Brief: Galecto Q2 Operating Income USD -3.421 Million
05/08/2025 21:15
Aug 05 (Reuters) - Galecto Q2 operating expenses USD 3.421 million. Q2 basic EPS USD -2.6 Q2 net income USD -3.437 million
Recent news on Damora Therapeutics
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Brief: Damora Therapeutics Reports First Quarter 2026 Financial Results
Brief: Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing